Despite the availability of several noninvasive tests for colorectal cancer, prioritizing blood-based tests may result in higher costs and worse population-level outcomes.
Adding serial circulating tumor DNA (ctDNA) assays to standard of care imaging surveillance had limited clinical benefits in patients with resected colorectal cancer (CRC).
How does age, sex, comorbidity, and screening history influence the cost-effectiveness of continuing colorectal cancer (CRC) screening in older adults?